Reactive oxygen species–associated molecular signature predicts survival in patients with sepsis
AffiliationUniv Arizona, Dept Med
Univ Arizona, Dept Biomed Engn
MetadataShow full item record
PublisherUNIV CHICAGO PRESS
CitationReactive oxygen species–associated molecular signature predicts survival in patients with sepsis 2016, 6 (2):196 Pulmonary Circulation
Rights© 2016 by the Pulmonary Vascular Research Institute. All rights reserved.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractSepsis-related multiple organ dysfunction syndrome is a leading cause of death in intensive care units. There is overwhelming evidence that oxidative stress plays a significant role in the pathogenesis of sepsis-associated multiple organ failure; however, reactive oxygen species (ROS)-associated biomarkers and/or diagnostics that define mortality or predict survival in sepsis are lacking. Lung or peripheral blood gene expression analysis has gained increasing recognition as a potential prognostic and/or diagnostic tool. The objective of this study was to identify ROS-associated biomarkers predictive of survival in patients with sepsis. In-silico analyses of expression profiles allowed the identification of a 21-gene ROS-associated molecular signature that predicts survival in sepsis patients. Importantly, this signature performed well in a validation cohort consisting of sepsis patients aggregated from distinct patient populations recruited from different sites. Our signature outperforms randomly generated signatures of the same signature gene size. Our findings further validate the critical role of ROSs in the pathogenesis of sepsis and provide a novel gene signature that predicts survival in sepsis patients. These results also highlight the utility of peripheral blood molecular signatures as biomarkers for predicting mortality risk in patients with sepsis, which could facilitate the development of personalized therapies.
NoteOn an institutional repository or open access repository after 12 months embargo.
VersionFinal published version
SponsorsVeterans Administration Health System grant [1IK2BX001477]; National Institutes of Health [R01HL91899]